company background image
PACB logo

Pacific Biosciences of California NasdaqGS:PACB Stock Report

Last Price

US$1.66

Market Cap

US$452.1m

7D

2.5%

1Y

-87.1%

Updated

22 Jul, 2024

Data

Company Financials +

Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$452.1m

Pacific Biosciences of California, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacific Biosciences of California
Historical stock prices
Current Share PriceUS$1.66
52 Week HighUS$13.70
52 Week LowUS$1.16
Beta2.04
11 Month Change12.93%
3 Month Change12.93%
1 Year Change-87.12%
33 Year Change-94.53%
5 Year Change-68.26%
Change since IPO-89.90%

Recent News & Updates

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

Recent updates

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Aug 08
Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

Jul 27

Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Jul 11
Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Shareholder Returns

PACBUS Life SciencesUS Market
7D2.5%-1.2%-2.1%
1Y-87.1%-8.3%19.0%

Return vs Industry: PACB underperformed the US Life Sciences industry which returned -8.3% over the past year.

Return vs Market: PACB underperformed the US Market which returned 19% over the past year.

Price Volatility

Is PACB's price volatile compared to industry and market?
PACB volatility
PACB Average Weekly Movement17.5%
Life Sciences Industry Average Movement7.8%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: PACB's share price has been volatile over the past 3 months.

Volatility Over Time: PACB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2000796Christian O. Henrywww.pacb.com

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.

Pacific Biosciences of California, Inc. Fundamentals Summary

How do Pacific Biosciences of California's earnings and revenue compare to its market cap?
PACB fundamental statistics
Market capUS$452.11m
Earnings (TTM)-US$296.90m
Revenue (TTM)US$200.43m

2.3x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PACB income statement (TTM)
RevenueUS$200.43m
Cost of RevenueUS$139.55m
Gross ProfitUS$60.88m
Other ExpensesUS$357.78m
Earnings-US$296.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 07, 2024

Earnings per share (EPS)-1.09
Gross Margin30.37%
Net Profit Margin-148.13%
Debt/Equity Ratio137.5%

How did PACB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.